PT3490535T - Composição de libertação sustentada compreendendo tolcapona micronizada - Google Patents
Composição de libertação sustentada compreendendo tolcapona micronizadaInfo
- Publication number
- PT3490535T PT3490535T PT177433588T PT17743358T PT3490535T PT 3490535 T PT3490535 T PT 3490535T PT 177433588 T PT177433588 T PT 177433588T PT 17743358 T PT17743358 T PT 17743358T PT 3490535 T PT3490535 T PT 3490535T
- Authority
- PT
- Portugal
- Prior art keywords
- sustained release
- release composition
- tolcapone
- micronized
- micronized tolcapone
- Prior art date
Links
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 title 1
- 229960004603 tolcapone Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16382372.7A EP3275433A1 (en) | 2016-07-29 | 2016-07-29 | Sustained release composition comprising micronized tolcapone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3490535T true PT3490535T (pt) | 2021-09-30 |
Family
ID=56571284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT177433588T PT3490535T (pt) | 2016-07-29 | 2017-07-28 | Composição de libertação sustentada compreendendo tolcapona micronizada |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11883538B2 (pt) |
| EP (2) | EP3275433A1 (pt) |
| JP (1) | JP7047236B2 (pt) |
| KR (1) | KR102484678B1 (pt) |
| CN (1) | CN109789100A (pt) |
| AU (1) | AU2017303333B2 (pt) |
| BR (1) | BR112019001826A2 (pt) |
| CA (1) | CA3032211A1 (pt) |
| DK (1) | DK3490535T3 (pt) |
| ES (1) | ES2891355T3 (pt) |
| MX (1) | MX2019001190A (pt) |
| PT (1) | PT3490535T (pt) |
| RU (1) | RU2750670C2 (pt) |
| WO (1) | WO2018019997A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024081554A2 (en) * | 2022-10-10 | 2024-04-18 | Corino Therapeutics, Inc. | Modified release tolcapone formulations |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5236952A (en) | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
| CN1129429C (zh) * | 1996-05-20 | 2003-12-03 | G·D·瑟尔公司 | 钾、钠和三羟甲基氨基甲烷噁丙嗪盐药物配方 |
| AU3705799A (en) | 1998-04-09 | 1999-11-01 | F. Hoffmann-La Roche Ag | Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants |
| US6599530B2 (en) * | 1998-09-14 | 2003-07-29 | Orion Corporation | Oral compacted composition comprising catechol derivatives |
| GB2348371B (en) * | 2000-03-14 | 2001-04-04 | Soares Da Silva Patricio | Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease |
| CA2510319A1 (en) * | 2002-12-20 | 2004-07-15 | Thomas J. Smith | High pressure compaction for pharmaceutical formulations |
| WO2006131591A2 (en) * | 2005-06-08 | 2006-12-14 | Orion Corporation | An entacapone-containing oral dosage form |
| JPWO2008087882A1 (ja) * | 2007-01-15 | 2010-05-06 | キッセイ薬品工業株式会社 | 胃内滞留型レボドパ徐放性製剤 |
| AU2011330757B2 (en) | 2010-11-15 | 2016-05-26 | Neuroderm Ltd | Continuous administration of L-dopa, dopa decarboxylase inhibitors, catechol-O-methyl transferase inhibitors and compositions for same |
| AU2012327275B2 (en) * | 2011-10-24 | 2017-03-02 | Som Innovation Biotech, S.L. | New therapy for transthyretin-associated amyloidosis |
| US20130195973A1 (en) * | 2012-01-30 | 2013-08-01 | Ranbaxy Laboratories Limited | Extended release pharmaceutical dosage forms of carbidopa and levodopa and process of preparation thereof |
| RU2677278C2 (ru) * | 2013-03-13 | 2019-01-16 | Неуродерм Лтд | Способ лечения болезни паркинсона |
| CA2929410C (en) * | 2013-11-05 | 2021-11-09 | Synagile Corporation | Devices and methods for continuous drug delivery via the mouth |
| WO2016036308A1 (en) * | 2014-09-04 | 2016-03-10 | Lobsor Pharmaceuticals Aktiebolag | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof |
-
2016
- 2016-07-29 EP EP16382372.7A patent/EP3275433A1/en not_active Withdrawn
-
2017
- 2017-07-28 KR KR1020197004664A patent/KR102484678B1/ko active IP Right Grant
- 2017-07-28 AU AU2017303333A patent/AU2017303333B2/en active Active
- 2017-07-28 DK DK17743358.8T patent/DK3490535T3/da active
- 2017-07-28 ES ES17743358T patent/ES2891355T3/es active Active
- 2017-07-28 CN CN201780060604.7A patent/CN109789100A/zh active Pending
- 2017-07-28 MX MX2019001190A patent/MX2019001190A/es unknown
- 2017-07-28 JP JP2019526375A patent/JP7047236B2/ja active Active
- 2017-07-28 WO PCT/EP2017/069168 patent/WO2018019997A1/en unknown
- 2017-07-28 EP EP17743358.8A patent/EP3490535B1/en active Active
- 2017-07-28 BR BR112019001826-3A patent/BR112019001826A2/pt active IP Right Grant
- 2017-07-28 CA CA3032211A patent/CA3032211A1/en active Pending
- 2017-07-28 RU RU2019103647A patent/RU2750670C2/ru active
- 2017-07-28 PT PT177433588T patent/PT3490535T/pt unknown
- 2017-07-28 US US16/321,336 patent/US11883538B2/en active Active
-
2024
- 2024-01-29 US US18/425,739 patent/US20240216282A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019001190A (es) | 2019-09-06 |
| US20240216282A1 (en) | 2024-07-04 |
| RU2019103647A (ru) | 2020-08-28 |
| CN109789100A (zh) | 2019-05-21 |
| CA3032211A1 (en) | 2018-02-01 |
| US11883538B2 (en) | 2024-01-30 |
| DK3490535T3 (da) | 2021-10-04 |
| WO2018019997A1 (en) | 2018-02-01 |
| JP2019523305A (ja) | 2019-08-22 |
| EP3275433A1 (en) | 2018-01-31 |
| RU2019103647A3 (pt) | 2020-10-12 |
| AU2017303333B2 (en) | 2023-03-30 |
| US20190167596A1 (en) | 2019-06-06 |
| EP3490535B1 (en) | 2021-07-14 |
| AU2017303333A1 (en) | 2019-03-14 |
| JP7047236B2 (ja) | 2022-04-05 |
| BR112019001826A2 (pt) | 2019-05-07 |
| RU2750670C2 (ru) | 2021-06-30 |
| EP3490535A1 (en) | 2019-06-05 |
| KR20190034563A (ko) | 2019-04-02 |
| KR102484678B1 (ko) | 2023-01-03 |
| ES2891355T3 (es) | 2022-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1225334A1 (zh) | 延遲釋放的香料組合物 | |
| IL250568B (en) | Anti-methanogenic preparations and their uses | |
| IL264446A (en) | Compounds and compositions and their use | |
| GB201502002D0 (en) | Uses and compositions | |
| GB201608762D0 (en) | Compositions and uses thereof | |
| IL260050B (en) | Dendrimers and preparations containing them | |
| IL270273B1 (en) | Highly charged drug formulations with enhanced sustained release | |
| IL264445A (en) | Compounds and compositions and their use | |
| IL263040A (en) | Pharmaceutical composition comprising eteplirsen | |
| IL249695A0 (en) | Converted polymyxins and preparations containing them | |
| HK1250915A1 (zh) | 組合物和其用途 | |
| GB201501991D0 (en) | Uses and compositions | |
| GB201502026D0 (en) | Uses and compositions | |
| ZA201901222B (en) | Composition comprising duddingtonia flagrans | |
| IL248863A0 (en) | Preparations containing il-31 and their use | |
| PT3490535T (pt) | Composição de libertação sustentada compreendendo tolcapona micronizada | |
| HK1258228A1 (zh) | 延長釋放型芳香劑組合物 | |
| HUE065294T2 (hu) | Késleltetett nyújtott hatóanyag-leadású gyógyszerkészítmények | |
| HUE057830T2 (hu) | Famitinib tartalmú gyógyszerkészítmény | |
| GB201614897D0 (en) | Compositions and uses thereof | |
| GB201602409D0 (en) | Compositions and uses thereof | |
| GB201522814D0 (en) | Compositions and uses thereof | |
| GB201511886D0 (en) | Uses and compositions | |
| HK1259452A1 (zh) | 脂質組合物及其用途 | |
| ZA201903341B (en) | Pharmaceutical compositions and uses thereof |